A revolutionary oral HBV treatment candidate as innovative therapeutic approach warranting clinical trials
Open Access
- 25 March 2024
- journal article
- editorial
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 59 (5) , 434-435
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- A novel, small anti-HBV compound reduces HBsAg and HBV-DNA by destabilizing HBV-RNAJournal of Gastroenterology, 2024
- Unexpected neurotoxicity in chronic toxicity studies with a HBV viral expression inhibitorRegulatory Toxicology and Pharmacology, 2023
- Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B InfectionNew England Journal of Medicine, 2022
- Combination treatment of a PAPD5/7 inhibitor with an antisense oligonucleotide bepirovirsen with concurrent dosing shows additive HBsAg decreases in the AAV-HBV mouse modelJournal of Hepatology, 2022
- Immune therapies against chronic hepatitis BJournal of Gastroenterology, 2022
- Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infectionJournal of Hepatology, 2022
- How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?Journal of Hepatology, 2022
- Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infectionJournal of Hepatology, 2022
- A novel orally available small molecule that inhibits hepatitis B virus expressionJournal of Hepatology, 2018
- First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex BJournal of Hepatology, 2016